These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 12862505)

  • 1. Drug interactions with angiotensin receptor blockers: a comparison with other antihypertensives.
    Unger T; Kaschina E
    Drug Saf; 2003; 26(10):707-20. PubMed ID: 12862505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450.
    Yang R; Luo Z; Liu Y; Sun M; Zheng L; Chen Y; Li Y; Wang H; Chen L; Wu M; Zhao H
    Curr Drug Metab; 2016; 17(7):681-91. PubMed ID: 27216792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of cytochrome P450 interactions when prescribing medication for hypertension.
    Flockhart DA; Tanus-Santos JE
    Arch Intern Med; 2002 Feb; 162(4):405-12. PubMed ID: 11863472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
    Baumgart P; Reismann J; Pohlmeyer H; Düsing R
    Dtsch Med Wochenschr; 2001 May; 126(19):547-50. PubMed ID: 11402910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Candesartan cilexetil: an angiotensin II receptor blocker.
    Stoukides CA; McVoy HJ; Kaul AF
    Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
    Petrella R; Michailidis P
    Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
    Scheen AJ
    Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug interactions with angiotensin receptor blockers.
    Böhler S; Pittrow D; Bramlage P; Kirch W
    Expert Opin Drug Saf; 2005 Jan; 4(1):7-18. PubMed ID: 15709894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative antihypertensive effects of angiotensin II receptor antagonists.
    Burnier M; Brunner HR
    J Am Soc Nephrol; 1999 Apr; 10 Suppl 12():S278-82. PubMed ID: 10201883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological properties of angiotensin II receptor antagonists.
    Timmermans PB
    Can J Cardiol; 1999 Nov; 15 Suppl F():26F-8F. PubMed ID: 10579749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.
    Thomas GN; Chan P; Tomlinson B
    Drugs Aging; 2006; 23(2):131-55. PubMed ID: 16536636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of angiotensin II antagonists in the treatment of hypertension].
    Gerc V
    Med Arh; 2002; 56(3):167-73. PubMed ID: 12378864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
    White WB; Lacourciere Y; Davidai G
    Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sympatho-inhibitory properties of various AT1 receptor antagonists.
    Balt JC; Mathy MJ; Pfaffendorf M; van Zwieten PA
    J Hypertens Suppl; 2002 Jun; 20(5):S3-11. PubMed ID: 12184061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of irbesartan in the management of hypertension.
    Bramlage P; Durand-Zaleski I; Desai N; Pirk O; Hacker C
    Expert Opin Pharmacother; 2009 Aug; 10(11):1817-31. PubMed ID: 19601700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valsartan. Just a second-line antihypertensive drug.
    Can Fam Physician; 1999 Nov; 45():2626-8, 2630-3. PubMed ID: 10587770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antihypertensive drug therapy: adverse effects and drug interactions].
    Takishita S
    Nihon Rinsho; 2001 May; 59(5):992-7. PubMed ID: 11392004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AT(1)-receptor blockers: differences that matter.
    Gradman AH
    J Hum Hypertens; 2002 Aug; 16 Suppl 3():S9-S16. PubMed ID: 12140723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist.
    Ruilope L
    J Hypertens Suppl; 1997 Dec; 15(7):S15-20. PubMed ID: 9532516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
    He YL; Ligueros-Saylan M; Sunkara G; Sabo R; Zhao C; Wang Y; Campestrini J; Pommier F; Dole K; Marion A; Dole WP; Howard D
    J Clin Pharmacol; 2008 Jan; 48(1):85-95. PubMed ID: 17986525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.